Boston Partners Pacira Bio Sciences, Inc. Transaction History

Boston Partners

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$25.5 - $31.51 $227,128 - $280,659	8,907 Added 42.27%	29,977 $857,000
Q1 2024 May 13, 2024	SELL	$27.7 - $35.48 $1.02 Million - $1.3 Million	-36,748 Reduced 63.56%	21,070 $615,000
Q4 2023 Feb 07, 2024	SELL	$26.32 - $34.31 $1.33 Million - $1.74 Million	-50,691 Reduced 46.72%	57,818 $1.95 Million
Q3 2023 Nov 07, 2023	BUY	$30.68 - $40.09 $1.71 Million - $2.23 Million	55,679 Added 105.39%	108,509 $3.33 Million
Q2 2023 Aug 10, 2023	SELL	$36.12 - $47.5 $898,665 - $1.18 Million	-24,880 Reduced 32.02%	52,830 $2.12 Million
Q1 2023 May 09, 2023	BUY	$35.53 - $43.38 $5,542 - $6,767	156 Added 0.2%	77,710 $3.17 Million
Q4 2022 Feb 07, 2023	SELL	$38.19 - $57.45 $879,706 - $1.32 Million	-23,035 Reduced 22.9%	77,554 $2.99 Million
Q3 2022 Nov 09, 2022	BUY	$51.24 - $58.89 $2.88 Million - $3.31 Million	56,282 Added 127.03%	100,589 $5.35 Million
Q2 2022 Aug 10, 2022	BUY	$51.49 - $81.64 $18,639 - $29,553	362 Added 0.82%	44,307 $2.58 Million
Q1 2022 May 10, 2022	BUY	$60.03 - $76.49 $1.94 Million - $2.47 Million	32,351 Added 279.03%	43,945 $3.35 Million
Q4 2021 Feb 04, 2022	BUY	$47.97 - $62.21 $556,164 - $721,262	11,594 New	11,594 $698,000

263

50.4M

429K

391K

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $892M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

Get notified when there are updates to the investment portfolio of Boston Partners, based on Form 13F filings with the SEC.

Stay updated on Boston Partners with notifications on news.